Redcare Pharmacy stock falls 3.33 percent on Xetra

Published on 09/25/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock reported Q2 revenue of EUR 853.5 million versus EUR 837.3 million forecast on July 29, 2026. EPS reached EUR 0.23 against a forecast loss of EUR 0.30.

Flatlay mit Aktienzertifikat, ISIN-Karte, Pillenblistern und Stethoskop von oben — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt Flatlay mit Aktienzertifikat, ISIN-Karte und markenfreien Apotheken-Utensilien, Illustration mit AI erstellt.

Redcare Pharmacy stock (ISIN NL0012044747) fell 3.33 percent on Xetra to EUR 59.45 on September 24, 2026, from EUR 61.50. The latest quarterly snapshot showed revenue ahead of forecast, while the share price remained below its September 17 close of EUR 59.90 after a volatile month.

Q2 revenue beat forecast

Investing.com lists the July 29, 2026 release with revenue of EUR 853.5 million against a EUR 837.3 million forecast. The difference was EUR 16.2 million, or 1.9 percent above the forecast.

The same release lists EPS of EUR 0.23 against a forecast of minus EUR 0.30. That comparison gives the operating update a stronger earnings signal than the daily price action alone, although the figures do not remove the stock's sensitivity to execution expectations.

Analyst targets stay higher

According to MarketScreener on September 1, 2026, Deutsche Bank analyst Jan Koch kept a Buy rating and a EUR 103 price target. The target was unchanged, leaving the analyst view focused on the company's execution rather than a new target-price catalyst.

MarketScreener reported on September 3, 2026 that Jefferies also maintained a Buy rating, with a EUR 97 price target. Two unchanged targets above the September 24 price frame the market debate around growth delivery and profitability.

Leadership date adds a checkpoint

Redcare Pharmacy has also set a management transition for October 1, 2026, when Peter Schmid von Linstow is scheduled to become chief executive officer, according to the Financial Times. The same company notice identifies Redcare Pharmacy as a Frankfurt Prime Standard listing and a member of the SDAX.

Xetra close shows pressure

Redcare Pharmacy closed at EUR 59.45 on Xetra on September 24, 2026, down 3.33 percent from EUR 61.50, with a session high of EUR 61.75, a low of EUR 59.45, and volume of 59.34K shares. The next scheduled earnings release is October 28, 2026, giving the market a defined checkpoint for the revenue and EPS trajectory.